Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.

Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA.

Cancer Immunol Res. 2015 Aug;3(8):855-63. doi: 10.1158/2326-6066.CIR-15-0024. Epub 2015 May 26.

2.

Targeting pathways downstream of KRAS in lung adenocarcinoma.

Zhu Z, Golay HG, Barbie DA.

Pharmacogenomics. 2014 Aug;15(11):1507-18. doi: 10.2217/pgs.14.108.

3.

Targeting cytokine networks in KRAS-driven tumorigenesis.

Golay HG, Barbie DA.

Expert Rev Anticancer Ther. 2014 Aug;14(8):869-71. doi: 10.1586/14737140.2014.928596. Epub 2014 Jun 13.

PMID:
24928447

Supplemental Content

Loading ...
Support Center